D
Daniel J. Stieh
Researcher at Janssen Pharmaceutica
Publications - 30
Citations - 1182
Daniel J. Stieh is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 14, co-authored 24 publications receiving 917 citations. Previous affiliations of Daniel J. Stieh include St George's Hospital & Northwestern University.
Papers
More filters
Journal ArticleDOI
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch,Dan H. Barouch,Frank Tomaka,Frank Wegmann,Daniel J. Stieh,Galit Alter,Merlin L. Robb,Merlin L. Robb,Nelson L. Michael,Lauren Peter,Joseph P. Nkolola,Erica N. Borducchi,Abishek Chandrashekar,David Jetton,Kathryn E. Stephenson,Kathryn E. Stephenson,Wenjun Li,Bette T. Korber,Georgia D. Tomaras,David C. Montefiori,Glenda Gray,Nicole Frahm,M. Juliana McElrath,Lindsey R. Baden,Jennifer Johnson,Julia Hutter,Edith Swann,Etienne Karita,Hannah Kibuuka,Juliet Mpendo,Nigel Garrett,Kathy Mngadi,Kundai Chinyenze,Frances Priddy,Erica Lazarus,Fatima Laher,Sorachai Nitayapan,Punnee Pitisuttithum,Stephan Bart,Thomas B. Campbell,Robert Feldman,Gregg Lucksinger,Caroline Borremans,Katleen Callewaert,Raphaele Roten,Jerald C. Sadoff,Lorenz Scheppler,Mo Weijtens,Karin Feddes-de Boer,Danielle van Manen,Jessica Vreugdenhil,Roland Zahn,Ludo Lavreys,Steven Nijs,Jeroen Tolboom,Jenny Hendriks,Zelda Euler,Maria G. Pau,Hanneke Schuitemaker +58 more
TL;DR: All vaccine regimens demonstrated favourable safety and tolerability and immunogenicity and protective efficacy against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3).
Journal ArticleDOI
Th17 Cells Are Preferentially Infected Very Early after Vaginal Transmission of SIV in Macaques.
Daniel J. Stieh,Edgar Matias,Huanbin Xu,Angela J. Fought,James Blanchard,Preston A. Marx,Ronald S. Veazey,Thomas J. Hope +7 more
TL;DR: This analysis identifies Th17-lineage CCR6+ CD4+ T cells as primary targets of SIV during vaginal transmission, which opens new opportunities for interventions to protect these cells and prevent HIV transmission.
Journal ArticleDOI
Human cervicovaginal mucus contains an activity that hinders HIV-1 movement.
Shetha Shukair,Shannon A. Allen,Gianguido C. Cianci,Daniel J. Stieh,Meegan R. Anderson,Samir M. Baig,Casey J. Gioia,Eric J. Spongberg,Sarah M. Kauffman,Michael D. McRaven,Howard Y. Lakougna,Cassing Hammond,Patrick F. Kiser,Thomas J. Hope +13 more
TL;DR: A previously unknown activity in CVM is revealed that is capable of impeding HIV-1 mobility to enhance mucosal barrier function and was significantly hindered in the same CVM samples in which bead diffusion was unhindered.
Journal ArticleDOI
Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models
TL;DR: Data presented here indicate that targeting HIV envelope glycoproteins may provide an effective strategy to prevent HIV-1 infection mediated by either cell-free virus or infected cells.
Journal ArticleDOI
Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract.
Daniel J. Stieh,Danijela Maric,Z. L. Kelley,Meegan R. Anderson,Holly Z. Hattaway,Beth Beilfuss,Katharina B. Rothwangl,Ronald S. Veazey,Thomas J. Hope +8 more
TL;DR: It is essential that protective mechanisms for prevention of HIV acquisition must be present at protective levels throughout the entire FRT to provide complete protection.